# US 2016/0250161 A1 · Compositions for the treatment of cns-related conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250161 A1
- Document ID: US20160250161A1
- Status: Published application
- Kind: A1
- Application number: 15/142,492
- Filed: 2016-04-29
- Published: 2016-09-01
- Earliest claimed: 2004-11-23
- Assignees: Adamas Pharmaceuticals, Inc.
- Applicants: Adamas Pharmaceuticals, Inc.
- Inventors: Gregory T. Went; Timothy J. Fultz; Laurence R. Meyerson
- Web page: https://patentgrep.com/patent/US20160250161A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2813: {Inorganic compounds}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/7061: {Polyacrylates}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.

## Claims

### Claim 1

A method of treating a patient with a neurological condition, comprising orally administering to a human subject in need thereof:
(a) 22.5 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof provided in a sustained release dosage form, wherein said sustained release memantine provides a change in mean plasma concentration of memantine as a function of time (dC/dT) that is: (1) less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0-Tmax of the immediate release form of memantine; and (2) 2.1 ng/ml/hr or less, determined in a time period of 0 to 4 hours; wherein dC/dT is measured in a single-dose human PK study; and
(b) a therapeutically effective amount of immediate release donepezil.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.

### Claim 3 (depends on 1)

The method of claim 1, wherein the neurological condition is selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain.

### Claim 4 (depends on 3)

The method of claim 3, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sustained release oral dosage form comprises 25 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.

### Claim 7 (depends on 6)

The method of claim 6, wherein the neurological condition is selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain.

### Claim 8 (depends on 5)

The method of claim 5, wherein the neurological condition is selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain.

### Claim 9 (depends on 1)

The method of claim 1, wherein the sustained release oral dosage form comprises 28 mg memantine or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.
